Predicted Effects of Treatment for HCV Infection Vary Among European Countries

S. Pol, R.H. Ghalib, V.K. Rustgi, C. Martorell, G.T. Everson, H.A. Tatum, C. Hezode, J.K. Lim, J.-P. Bronowicki, G.A. Abrams, N. Brau, D.W. Morris, P. Thuluvath, R. Reindollar, P.D. Yin, U. Diva, R. Hindes, F. McPhee, M. Gao, A. Thiry, S. Schnittman, E.A. Hughes, 1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS Journal of Hepatology. ,vol. 54, pp. 544- 545 ,(2011) , 10.1016/S0168-8278(11)61375-5

Christophe Hézode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, Tobias Goeser, Jean-Pierre Bronowicki, Marc Bourlière, Shahin Gharakhanian, Leif Bengtsson, Lindsay McNair, Shelley George, Tara Kieffer, Ann Kwong, Robert S. Kauffman, John Alam, Jean-Michel Pawlotsky, Stefan Zeuzem, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine. ,vol. 360, pp. 1839- 1850 ,(2009) , 10.1056/NEJMOA0807650

Y. Futagawa, P. I. Terasaki, K. Waki, J. Cai, D. W. Gjertson, No Improvement in Long‐Term Liver Transplant Graft Survival in the Last Decade: An Analysis of the UNOS Data American Journal of Transplantation. ,vol. 6, pp. 1398- 1406 ,(2006) , 10.1111/J.1600-6143.2006.01256.X

Tommaso Stroffolini, Franco Trevisani, Giovanbattista Pinzello, Franco Brunello, Maurizio A. Tommasini, Massimo Iavarone, Vito Di Marco, Fabio Farinati, Paolo Del Poggio, Franco Borzio, Mauro Borzio, Eugenio Caturelli, Maria Anna Di Nolfo, Marta Frigerio, Giuseppina Brancaccio, Giovanni Battista Gaeta, Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance Digestive and Liver Disease. ,vol. 43, pp. 875- 880 ,(2011) , 10.1016/J.DLD.2011.05.002

Hashem B El-Serag, Andrew C Mason, Charles Key, Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States Hepatology. ,vol. 33, pp. 62- 65 ,(2001) , 10.1053/JHEP.2001.21041

Kazuaki Chayama, Shoichi Takahashi, Joji Toyota, Yoshiyasu Karino, Kenji Ikeda, Hiroki Ishikawa, Hideaki Watanabe, Fiona McPhee, Eric Hughes, Hiromitsu Kumada, Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders†‡§ Hepatology. ,vol. 55, pp. 742- 748 ,(2012) , 10.1002/HEP.24724

Thierry Poynard, Vlad Ratziu, Frédéric Charlotte, Zachary Goodman, John McHutchison, Janice Albrecht, Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C Journal of Hepatology. ,vol. 34, pp. 730- 739 ,(2001) , 10.1016/S0168-8278(00)00097-0

G Davis, Projecting future complications of chronic hepatitis C in the United States Liver Transplantation. ,vol. 9, pp. 331- 338 ,(2003) , 10.1053/JLTS.2003.50073

D Hüppe, E Zehnter, S Mauss, K Böker, T Lutz, S Racky, W Schmidt, J Ullrich, I Sbrijer, R Heyne, A Schober, C John, K.-H Hey, B Bokemeyer, B Kallinowski, B Möller, S Pape, M Gutmann, U Alshuth, C Niederau, [Epidemiology of chronic hepatitis C in Germany--an analysis of 10,326 patients in hepatitis centres and outpatient units]. Zeitschrift Fur Gastroenterologie. ,vol. 46, pp. 34- 44 ,(2008) , 10.1055/S-2007-963691

Filippo Ansaldi, Bianca Bruzzone, Stefania Salmaso, Maria Cristina Rota, Paolo Durando, Roberto Gasparini, Giancarlo Icardi, Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy Journal of Medical Virology. ,vol. 76, pp. 327- 332 ,(2005) , 10.1002/JMV.20376